SCHEMBL27002142

SCHEMBL27002142

CCCCCc1ccc(C=O)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.57
PPARA Q07869 1/20 0.57
ALDH1A1 P00352 3/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
LTA4H P09960 3/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C8 P10632 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2B6 P20813 2/20 0.47
CYP2C19 P33261 2/20 0.47
HTR1A P08908 3/20 0.46
CYP2E1 P05181 1/20 0.46
ALOX5 P09917 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2A6 P11509 1/20 0.46
TRPV1 Q8NER1 1/20 0.46
CDK1 P06493 1/20 0.45
KDM4E B2RXH2 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31455929 0.98 PPARG (0.59) PPARGPPARAALDH1A1L3MBTL1LTA4H
SCHEMBL31442610 0.98 PPARG (0.59) PPARGPPARAALDH1A1L3MBTL1LTA4H
SCHEMBL31455942 0.95 ALDH1A1 (0.53) PPARGPPARAALDH1A1L3MBTL1LTA4H
SCHEMBL465084 0.89 ALDH1A1 (0.56) PPARGPPARAALDH1A1L3MBTL1CYP3A4
SCHEMBL28038475 0.85 PPARA (0.51) PPARGPPARACDK1
SCHEMBL31442707 0.85 PPARA (0.48) PPARGPPARAL3MBTL1CDK1
SCHEMBL31442640 0.85 PPARA (0.48) PPARGPPARAL3MBTL1CDK1
SCHEMBL8323669 0.83 PPARG (0.48) PPARGPPARAALDH1A1L3MBTL1LTA4H
SCHEMBL9714792 0.82 ALDH1A1 (0.59) PPARGPPARAALDH1A1L3MBTL1KDM4E
SCHEMBL27328484 0.81 HTR1A (0.48) PPARGPPARAALDH1A1L3MBTL1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025059373-A1 NOVEL PHENALKYLAMINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS GILGAMESH PHARMACEUTICALS, INC. (US) 2025-03-20 WO disclosed
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2024-05-23 US disclosed
CN-117642379-A Phenylalkylamines and methods of making and using the same 吉尔伽美什制药公司 2024-03-01 CN disclosed
EP-4305019-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME Gilgamesh Pharmaceuticals, Inc. (US) 2024-01-17 EP disclosed
WO-2022192781-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME GILGAMESH PHARMACEUTICALS, INC. (US) 2022-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166618-A1 PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME PNMT, HTR6, HTR2C PPARG 1071/4885PPARA 592/4885ALDH1A1 1077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.